CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 12 enrolled
Drug / intervention
Testosterone enanthate auto-injectorcombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02233751
NCT02233751Phase 1Completed

An Open-Label Study to Evaluate the Pharmacokinetics of Testosterone Enanthate After Single-Dose Injection Via QuickShot® Testosterone in Healthy Male Subjects

Antares Pharma Inc.·interventional·Posted Sep 8, 2014·Updated Apr 19, 2019

In Brief

A Phase 1 clinical trial evaluating Testosterone enanthate auto-injector for Hypogonadism. Completed, enrolled 12 participants across 1 site.

Detailed Summary

Evaluation of pharmacokinetics of subcutaneous testosterone enanthate

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypogonadism
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 8, 2014
Enrollment StartSep 1, 2014
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 11.8 years ago

Interventions

Testosterone enanthate auto-injectorcombination

Randomization then administration of combination product study medication according to group assignment